Home ›
Adenocarcinoma Esophageal Cancer Trials ›
NCT05954312
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Trial Details
NCT ID NCT05954312
Phase PHASE1
Sponsor Vividion Therapeutics, Inc.
Status RECRUITING
Cancer Type Adenocarcinoma Esophageal Cancer
Interventions VVD-130037 Docetaxel Paclitaxel Pembrolizumab
Locations (sample) Jacksonville, Florida, United States|30.33218,-81.65565 Sarasota, Florida, United States|27.33643,-82.53065 Tampa, Florida, United States|27.94752,-82.45843 Rochester, Minnesota, United States|44.02163,-92.4699 Nashville, Tennessee, United States|36.16589,-86.78444
Key Eligibility Criteria
Histologically or cytologically confirmed metastatic or unresectable solid tumor. Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator. Have progressed on or after all prior standard-of-care therapies for metastatic disease. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
For full eligibility, visit ClinicalTrials.gov .